Mediastinal and hilar sarcoid‑like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature

Bala,Vanessa-Meletia; Mitsogianni,Maria; Laschos,Konstantinos; Pliakou,Evangelia; Lazaridi,Eirini; Lampropoulou,Dimitra-Ioanna; Aravantinos,Gerasimos

doi:10.3892/mco.2022.2532

Mediastinal and hilar sarcoid‑like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature

Authors:
- Vanessa-Meletia Bala
- Maria Mitsogianni
- Konstantinos Laschos
- Evangelia Pliakou
- Eirini Lazaridi
- Dimitra-Ioanna Lampropoulou
- Gerasimos Aravantinos
View Affiliations

Affiliations: 2nd Department of Medical Oncology, General Oncology Hospital of Kifissia ‘Agioi Anargyroi’, Athens 145 64, Greece
Published online on: March 18, 2022 https://doi.org/10.3892/mco.2022.2532
Article Number: 99

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

BRAF/MEK inhibitors are considered standard of care in the treatment of advanced BRAF‑mutated malignant melanoma, and have been, in rare cases, associated with granulomatous reactions, mostly limited to skin lesions. The present study reported the case of a patient with metastatic melanoma developing a sarcoid‑like reaction manifesting as asymptomatic mediastinal and right hilar lymphadenopathy while on antineoplastic therapy with dabrafenib and trametinib. To the best of our knowledge, this is the first reported case of isolated lymphadenopathy as a manifestation of drug‑induced sarcoid‑like reaction under dabrafenib and trametinib. Overall, only 17 other cases of granulomatosis have been reported in the literature. Although uncommon, such reactions should be considered in the differential diagnosis of lymph node enlargement, and distinguishing them from tumor progress is important and can be challenging in clinical practice.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.PubMed/NCBI View Article : Google Scholar
2	Rubin KM and Lawrence DP: Your patient with melanoma: Staging, prognosis, and treatment. Oncology (Williston Park). 23 (Suppl 8):S13–S21. 2009.PubMed/NCBI
3	Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R and Keilholz U: ESMO Guidelines Committee. Electronic address: simpleclinicalguidelines@esmo.org. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 30:1884–1901. 2019.PubMed/NCBI View Article : Google Scholar
4	Mandalà M and Voit C: Targeting BRAF in melanoma: Biological and clinical challenges. Crit Rev Oncol Hematol. 87:239–255. 2013.PubMed/NCBI View Article : Google Scholar
5	El Jammal T, Pavic M, Gerfaud-Valentin M, Jamilloux Y and Sève P: Sarcoidosis and cancer: A complex relationship. Front Med (Lausanne). 7(594118)2020.PubMed/NCBI View Article : Google Scholar
6	Seve P, Schott AM, Pavic M, Broussolle C, Gilis L and Thomas L: Sarcoidosis and melanoma: A referral center study of 1,199 cases. Dermatology. 219:25–31. 2009.PubMed/NCBI View Article : Google Scholar
7	Cohen Aubart F, Lhote R, Amoura A, Valeyre D, Haroche J, Amoura Z and Lebrun-Vignes B: Drug-induced sarcoidosis: An overview of the WHO pharmacovigilance database. J Intern Med. 288:356–362. 2020.PubMed/NCBI View Article : Google Scholar
8	Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA and Syrigos KN: Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. 13:1076–1082. 2018.PubMed/NCBI View Article : Google Scholar
9	Rubio-Rivas M, Moreira C and Marcoval J: Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma. Autoimmun Rev. 19(102587)2020.PubMed/NCBI View Article : Google Scholar
10	Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, Goldinger SM, Barysch M, Franzen D, Kamarachev J, Braun R, Dummer R and Mangana J: Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 28:230–236. 2018.PubMed/NCBI View Article : Google Scholar
11	Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA and Long GV: Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J Immunol. 192:2505–2513. 2014.PubMed/NCBI View Article : Google Scholar
12	Green JS, Norris DA and Wisell J: Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: A report of two cases. Br J Dermatol. 169:172–176. 2013.PubMed/NCBI View Article : Google Scholar
13	Park JJ, Hawryluk EB, Tahan SR, Flaherty K and Kim CC: Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol. 150:307–311. 2014.PubMed/NCBI View Article : Google Scholar
14	Jansen YJ, Janssens P, Hoorens A, Schreuer MS, Seremet T, Wilgenhof S and Neyns B: Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. Melanoma Res. 25:550–554. 2015.PubMed/NCBI View Article : Google Scholar
15	Winkler JK, Buder-Bakhaya K, Ellert E, Herpel E, Martens UM, Enk A and Hassel JC: Acute heart failure as a result of granulomatous myocarditis: Case report on a patient with metastatic melanoma treated with dabrafenib and trametinib. J Eur Acad Dermatol Venereol. 32:e31–e32. 2018.PubMed/NCBI View Article : Google Scholar
16	Rueda-Rueda T, Sánchez-Vicente JL, Moruno-Rodríguez A, Molina-Socola FE, Martínez-Borrego AC and López-Herrero F: Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib. Arch Soc Esp Oftalmol (Engl Ed). 93:458–462. 2018.PubMed/NCBI View Article : Google Scholar : (In English, Spanish).
17	Korman AM, Nisar MS and Somach SC: Subclinical granulomas in benign skin lesions heralding the onset of BRAF and MEK inhibitor-associated granulomatous dermatitis in a patient with metastatic melanoma. JAAD Case Rep. 4:722–724. 2018.PubMed/NCBI View Article : Google Scholar
18	Giet G, Lebas E, Rorive A, Arrese JE and Nikkels AF: Granulomatous reactions from tattoos following BRAF inhibitor therapy. Case Rep Dermatol. 11:101–107. 2019.PubMed/NCBI View Article : Google Scholar
19	Huynh S, Lheure C, Franck N, Goldman-Lévy G, Aractingi S, Dupin N, Kramkimel N and Guégan S: Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: A monocentric retrospective study. Melanoma Res. 30:317–320. 2020.PubMed/NCBI View Article : Google Scholar
20	Boutros A, Schiavi C, Cecchi F, Spagnolo F, Guadagno A, Tanda ET, Giusti F, Murdaca G and Queirolo P: Case report: Immune-related toxicity during adjuvant treatment with BRAF plus MEK inhibitors in a melanoma patient. Front Immunol. 11(579523)2020.PubMed/NCBI View Article : Google Scholar
21	Adam A, Thomas L, Bories N, Zaharia D, Balme B, Freymond N and Dalle S: Sarcoidosis associated with vemurafenib. Br J Dermatol. 169:206–208. 2013.PubMed/NCBI View Article : Google Scholar
22	Hui Ong EL, Sinha R, Jmor S and Fearfield L: BRAF inhibitor-associated granulomatous dermatitis: A report of 3 cases. Am J Dermatopathol. 41:214–217. 2019.PubMed/NCBI View Article : Google Scholar
23	Assan F, Schlemmer F, Assie JB, Mahevas M, Sustronck P, Ortonne N, Velter C, Fardet L and Zehou O: Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors. Eur J Dermatol. 29:556–557. 2019.PubMed/NCBI View Article : Google Scholar
24	Lheure C, Kramkimel N, Franck N, Laurent-Roussel S, Carlotti A, Queant A, Goldwasser F, Avril MF and Dupin N: Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: A paradoxical autoimmune activation. Dermatology. 231:378–384. 2015.PubMed/NCBI View Article : Google Scholar